LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

Evolent Health to Participate in Upcoming Conferences

August 08, 2023 | Last Trade: US$11.31 0.64 -5.36

WASHINGTON, Aug. 8, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences, including meetings with institutional investors and presentations.

A live audio-only webcast and replay for these events will be available, if applicable, on the Investor Relations section of Evolent's website at http://ir.evolenthealth.com.

  • Messrs. Blackley and Frank will present at the Canaccord Genuity CG Capital Markets 43rd Annual Growth Conference at the Intercontinental Boston, on Wednesday, August 9, 2023, at 11:00 a.m. ET.
     
  • Mr. Frank will present at the RBC Nashville Healthcare Bus Tour at the Westin Nashville, on Wednesday, August 16, 2023, at 12:00 p.m. ET.
     
  • Messrs. Johnson and Frank will present at the 2023 Bernstein Disruptor Conference in New York City, on Wednesday, October 4, 2023.

About Evolent

Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting www.evolenthealth.com.

Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent
This email address is being protected from spambots. You need JavaScript enabled to view it.
571-895-3919 (W)

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB